Theravance Biopharma, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that makes YUPELRI (revefenacin), a once-daily nebulized medicine that helps people with COPD breathe more easily, sold in the US with partner Viatris. It grew out of Theravance, Inc., founded in 1996, which split in 2014 into two public companies, with Theravance Biopharma keeping the respiratory drug pipeline. Its name blends "therapy" and "advance"—fitting for a firm built on advancing medicine.
Bought 2.50M
Granted 388.4K
Granted 212.5K
Granted 212.5K
Granted 15.0K · Sold 7.4K
Granted 136.5K · Sold 128.1K
Granted 141.7K
Granted 27.2K
Granted 27.2K
Granted 27.2K
Granted 27.2K
Granted 21.2K · Sold 74.5K
Granted 27.2K
Granted 33.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Samaha Eli10% owner · 3 transactions | — | 9.51Mas of Aug 2024 | — | 2.50M | — |
| Winningham Rick ECHIEF EXECUTIVE OFFICER, Director · 27 transactions | — | 1.73M | 388.4K | — | — |
| Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY · 15 transactions | +24.5% | 355.2K | 212.5K | — | — |
| Sawaf AzizSVP & CHIEF FINANCIAL OFFICER · 15 transactions | +28.6% | 336.8K | 212.5K | — | — |
| Graham Richard ASVP, RESEARCH & DEVELOPMENT · 6 transactions | -7.2% | 314.9Kas of Feb 2024 | 15.0K | — | 7.4K |
| Farnum RhondaSVP, COMM & MEDICAL AFFAIRS · 35 transactions | -33.4% | 226.8K | 136.5K | — | 128.1K |
| Miller AineSVP, DEV & HEAD OF IRE OFFICE · 15 transactions | — | 189.8K | 141.7K | — | — |
| Mitchell Dean JDirector · 3 transactions | +38.8% | 97.2K | 27.2K | — | — |
| Smaldone Alsup LaurieDirector · 3 transactions | +50.6% | 81.0K | 27.2K | — | — |
| O'Connor DonalDirector · 3 transactions | +51.3% | 80.2K | 27.2K | — | — |
| Pakianathan DeepikaDirector · 3 transactions | +73.7% | 64.1K | 27.2K | — | — |
| Broshy EranDirector · 7 transactions | -14% | 60.2K | 21.2K | — | 74.5K |
| Gray SusannahDirector · 3 transactions | +129.8% | 48.1K | 27.2K | — | — |
| Grant Jeremy TDirector · 4 transactions | — | 33.0Kas of May 2025 | 33.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +2.29M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.